1. Academic Validation
  2. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model

  • Cell Biochem Biophys. 2017 Dec;75(3-4):299-309. doi: 10.1007/s12013-017-0814-5.
H Gustafsson 1 2 A Kale 3 A Dasu 4 5 A Lund 6 P-H Edqvist 7 K Roberg 3
Affiliations

Affiliations

  • 1 Department of Radiology Norrköping and Department of Medical and Health Sciences (IMH), Linköping University, Linköping, Sweden. [email protected].
  • 2 Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden. [email protected].
  • 3 Division of Oto-Rhino-Laryngology and Head and Neck Surgery, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • 4 Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • 5 The Skandion Clinic, Uppsala, Sweden.
  • 6 Department of Physics, Chemistry and Biology (IFM), Linköping University, Linköping, Sweden.
  • 7 Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
Abstract

Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux®) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on female BALB/c (nu/nu) nude mice. Mice with xenografts were given three injections of intraperitoneal cetuximab or phosphate-buffered saline, and the tumour volume was recorded continuously. After treatment the tumour partial oxygen pressure was measured by LiPc electron paramagnetic resonance oximetry and the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Ki-67, MCT1, MCT4, GLUT1, CAIX and HIF-1α were investigated by immunohistochemistry. In xenografts from both cell lines (UT-SCC-2 and UT-SCC-14) cetuximab had effect on the tumour volume but the effect was more pronounced on UT-SCC-14 xenografts. A higher tumour oxygenation was measured in cetuximab-treated tumours from both cell lines compared to untreated controls. Immunocytochemical staining after cetuximab treatment shows a significantly decreased expression of EGFR, pEGFR, Ki67, CAIX and nuclear HIF-1α in UT-SCC-14 tumours compared to untreated controls. MCT1 and GLUT1 were significantly decreased in tumours from both cell lines but more pronounced in UT-SCC-14 tumours. Taken together, our results show that cetuximab treatment decreases the tumour growth and increases the tumour partial oxygen pressure of HNSCC xenografts. Furthermore we found a potential connection between the partial oxygen pressure of the tumours and the expression of proteins involved in tumour growth, metabolism and hypoxia.

Keywords

Cetuximab; EPR oximetry; Head and neck cancer; Hypoxia; Metabolism; Tumour oxygen pressure.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P9905
    99.70%, EGFR Inhibitor